We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension.
- Authors
Muraki, Yo; Naito, Takako; Tohyama, Kimio; Shibata, Sachio; Kuniyeda, Kanako; Nio, Yasunori; Hazama, Masatoshi; Matsuo, Takanori
- Abstract
Pulmonary hypertension (PH) is a life-threatening lung disease. PH with concomitant lung diseases, e.g., idiopathic pulmonary fibrosis, is associated with poor prognosis. Development of novel therapeutic vasodilators for treatment of these patients is a key imperative. We evaluated the efficacy of dual activation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) using an active, small-molecule phosphodiesterase (PDE4)/PDE5 dual inhibitor (Compound A). Compound A increased both cAMP and cGMP levels in WI-38 lung fibroblasts and suppressed the expressions of type-1 collagen α1 chain and fibronectin. Additionally, compound A reduced right ventricular weight/left ventricular weight+septal weight ratio, brain natriuretic peptide expression levels in right ventricle, C─C motif chemokine ligand 2 expression levels in lung, and plasma surfactant protein D. Our data indicate that dual activation of cAMP/cGMP pathways may be a novel treatment strategy for PH. Elevated cAMP suppresses profibrotic and inflammatory responses. Elevated cGMP enhances vasodilation and suppresses proliferation of smooth muscle cells.
- Subjects
HYPERTENSION; INFLAMMATION; MONOCROTALINE
- Publication
Bioscience, Biotechnology & Biochemistry, 2019, Vol 83, Issue 6, p1000
- ISSN
0916-8451
- Publication type
Article
- DOI
10.1080/09168451.2019.1584520